On this blog, we have already discussed the good news that the US Federal Trade Commission (FTC) is considering whether advertisements for homeopathic products have any evidence to back the numerous claims that are being made for them. A meeting took place on 21 September, and now the first details are emerging.
Michelle Rusk, senior staff attorney in the FTC advertising practices division, said in this public hearing on over-the-counter homeopathic products that advertisements lauding the health benefits of medical products need to be based on competent, reliable, and rigorous scientific support.
“As a general rule, for treatment claims, we expect randomized, double-blind, placebo-controlled human clinical studies—not in vitro studies, not animal studies, not anecdotal evidence, no matter how compelling it is,” she said. “Second, we expect the studies to be internally valid. That means well-designed, reliably conducted, using procedures accepted in the field of research. It also means that results are not just statistically significant but also strong enough to be clinically meaningful. Third, the evidence has to match the product and the specific claim.”
In the context of any form of health care, such statements would amount to mere platitudes: the fact that we cannot possibly tolerate double standards in medicine is almost too obvious to mention. In the realm of homeopathy, however, these words amount to a revolution!
Could it be that the days of bogus claims for homeopathic products are counted?
Could it be that consumers might soon be protected from unscrupulous entrepreneurs exploiting the vulnerable?
Could it be that, one day, we will have one standard only?